Chelsea Therapeutics Declines Most in Three Years

Chelsea Therapeutics International Ltd. plunged the most in about three years after U.S. regulators said a new trial may be needed for Northera, a drug for dizziness and fainting that would be its first marketed product.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.